These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 7544809)

  • 21. [Direct analysis of HBV-specific CD8+ lymphocyte by tetrameric HLA-A2/core 18-27 complex in chronic Hepatitis B].
    Lee CK; Suh JH; Cho YS; Han KH; Chung JB; Chon CY; Moon YM
    Taehan Kan Hakhoe Chi; 2002 Jun; 8(2):139-48. PubMed ID: 12499799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of cytotoxic T lymphocyte responses induced by peptide or DNA immunization: implications on immunogenicity and immunodominance.
    Vitiello A; Sette A; Yuan L; Farness P; Southwood S; Sidney J; Chesnut RW; Grey HM; Livingston B
    Eur J Immunol; 1997 Mar; 27(3):671-8. PubMed ID: 9079808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis B virus surface protein mutations clustered mainly in CTL immune epitopes in chronic carriers: results of an Iranian nationwide study.
    Khedive A; Norouzi M; Ramezani F; Karimzadeh H; Alavian SM; Malekzadeh R; Montazeri G; Nejatizadeh A; Ziaee M; Abedi F; Ataei B; Yaran M; Sayad B; Somi MH; Sarizadeh G; Sanei-Moghaddam I; Mansour-Ghanaei F; Rafatpanah H; Pourhosseingholi MA; Keyvani H; Kalantari E; Saberifiroozi M; Judaki MA; Ghamari S; Daram M; Mahabadi M; Fazeli Z; Goodarzi Z; Poortahmasebi V; Jazayeri SM
    J Viral Hepat; 2013 Jul; 20(7):494-501. PubMed ID: 23730843
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy.
    Boni C; Penna A; Ogg GS; Bertoletti A; Pilli M; Cavallo C; Cavalli A; Urbani S; Boehme R; Panebianco R; Fiaccadori F; Ferrari C
    Hepatology; 2001 Apr; 33(4):963-71. PubMed ID: 11283861
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The high prevalence of the I27 mutant HBcAg18-27 epitope in Chinese HBV-infected patients and its cross-reactivity with the V27 prototype epitope.
    Liu HG; Chen WW; Fan ZP; Yang HY; Shi M; Zhang Z; Luan SS; Zhang H; Lu P; Tien P; Wang FS
    Clin Immunol; 2007 Dec; 125(3):337-45. PubMed ID: 17900990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential cytotoxic T-lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients.
    Rehermann B; Chang KM; McHutchinson J; Kokka R; Houghton M; Rice CM; Chisari FV
    J Virol; 1996 Oct; 70(10):7092-102. PubMed ID: 8794355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of HLA-A3 and -B7-restricted CTL response to hepatitis C virus in patients with acute and chronic hepatitis C.
    Chang KM; Gruener NH; Southwood S; Sidney J; Pape GR; Chisari FV; Sette A
    J Immunol; 1999 Jan; 162(2):1156-64. PubMed ID: 9916747
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines.
    Guilhot S; Fowler P; Portillo G; Margolskee RF; Ferrari C; Bertoletti A; Chisari FV
    J Virol; 1992 May; 66(5):2670-8. PubMed ID: 1313893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B virus-DNA transfected myeloma cell-specific cytotoxic T cells in chronic hepatitis B patients.
    Kamogawa Y; Yamauchi K; Obata H; Chisaka O; Matsubara K
    Virology; 1992 Nov; 191(1):321-6. PubMed ID: 1413509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules.
    Livingston BD; Crimi C; Fikes J; Chesnut RW; Sidney J; Sette A
    Hum Immunol; 1999 Nov; 60(11):1013-7. PubMed ID: 10599997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Relationship between effect of lamivudine in the treatment of cirrhotic patients with uncompensated hepatitis B with HBV genotypes and cytotoxic T lymphocyte].
    Wang D; Gu XB; Zhu YF; Xiao-Juan Y; Jiang XH; Huang LH; Qiu YW; Wu HY; Yu P
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Aug; 27(4):283-5. PubMed ID: 24579476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular features of the hepatitis B virus nucleocapsid T-cell epitope 18-27: interaction with HLA and T-cell receptor.
    Bertoletti A; Southwood S; Chesnut R; Sette A; Falco M; Ferrara GB; Penna A; Boni C; Fiaccadori F; Ferrari C
    Hepatology; 1997 Oct; 26(4):1027-34. PubMed ID: 9328331
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A complete genomic analysis of hepatitis B virus isolated from 516 Chinese patients with different clinical manifestations.
    Li X; Liu Y; Xu Z; Wan Z; Bai S; Mao P; Mao Y; Xin S; Xu D
    J Med Virol; 2013 Oct; 85(10):1698-704. PubMed ID: 23852705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of hepatitis B virus-specific CTL epitopes presented by HLA-A*2402, the most common HLA class I allele in East Asia.
    Sobao Y; Sugi K; Tomiyama H; Saito S; Fujiyama S; Morimoto M; Hasuike S; Tsubouchi H; Tanaka K; Takiguch M
    J Hepatol; 2001 Jun; 34(6):922-9. PubMed ID: 11451178
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peptide-specific CTL induction in HBV-seropositive PBMC by stimulation with peptides in vitro: novel epitopes identified from chronic carriers.
    Lee HG; Lim JS; Lee KY; Choi YK; Choe IS; Chung TW; Kim K
    Virus Res; 1997 Aug; 50(2):185-94. PubMed ID: 9282783
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.
    Rehermann B; Ferrari C; Pasquinelli C; Chisari FV
    Nat Med; 1996 Oct; 2(10):1104-8. PubMed ID: 8837608
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of carriers of hepatitis B virus from a tertiary referral hospital: does the viral load change during the natural course of infection?
    Aakanksha ; Asim M; Sharma PK; Das BC; Kar P
    J Med Virol; 2011 Jul; 83(7):1151-8. PubMed ID: 21520137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Dynamic changes and clinical significance of HBcAg18-27 specific cytotoxic T lymphocytes in acute hepatitis B patients].
    Li J; Han YP; Liu B; Liu Y; Chen N; Dong L; Yan YD; Jiang LF; Huang ZH
    Zhonghua Gan Zang Bing Za Zhi; 2011 Jan; 19(1):38-43. PubMed ID: 21272457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group.
    Heathcote J; McHutchison J; Lee S; Tong M; Benner K; Minuk G; Wright T; Fikes J; Livingston B; Sette A; Chestnut R
    Hepatology; 1999 Aug; 30(2):531-6. PubMed ID: 10421664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells.
    Bertoletti A; Sette A; Chisari FV; Penna A; Levrero M; De Carli M; Fiaccadori F; Ferrari C
    Nature; 1994 Jun; 369(6479):407-10. PubMed ID: 8196768
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.